Literature DB >> 16168666

The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays.

Susan M Moore1, Teri A Ricke, Rolan D Davis, Deborah J Briggs.   

Abstract

The effect that the relatedness of the viral seed strain used to produce rabies vaccines has to the strain of challenge virus used to measure rabies virus neutralizing antibodies after vaccination was evaluated. Serum samples from 173 subjects vaccinated with either purified Vero cell rabies vaccine (PVRV), produced from the Pittman Moore (PM) seed strain of rabies virus, or purified chick embryo cell rabies vaccine (PCECV), produced from the Flury low egg passage (Flury-LEP) seed strain of rabies virus, were tested in parallel assays by RFFIT using a homologous and a heterologous testing system. In the homologous system, CVS-11 was used as the challenge virus in the assay to evaluate the humoral immune response in subjects vaccinated with PVRV and Flury-LEP was used for subjects vaccinated with PCECV. In the heterologous system, CVS-11 was used as the challenge virus in the assay to evaluate subjects vaccinated with PCECV and Flury-LEP was used for subjects vaccinated with PVRV. Although the difference in G protein homology between the CVS-11 and Flury-LEP rabies virus strains has been reported to be only 5.8%, the use of a homologous testing system resulted in approximately 30% higher titers for nearly two-thirds of the samples from both vaccine groups compared to a heterologous testing system. The evaluation of equivalence of the immune response after vaccination with the two different vaccines was dependent upon the type of testing system, homologous or heterologous, used to evaluate the level of rabies virus neutralizing antibodies. Equivalence between the vaccines was achieved when a homologous testing system was used but not when a heterologous testing system was used. The results of this study indicate that the strain of virus used in the biological assays to measure the level of rabies virus neutralizing antibodies after vaccination could profoundly influence the evaluation of rabies vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168666     DOI: 10.1016/j.biologicals.2005.06.005

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  12 in total

Review 1.  Rabies-specific antibodies: measuring surrogates of protection against a fatal disease.

Authors:  Susan M Moore; Cathleen A Hanlon
Journal:  PLoS Negl Trop Dis       Date:  2010-03-09

2.  Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India.

Authors:  Doddabele Hanumanthaiah Ashwath Narayana; Shampur Narayana Madhusudana; Gadey Sampath; Radhe Madhab Tripathy; Mysore Kalappa Sudarshan; Haradanahalli Shankaraiah Ravish; Durga Madhab Satapathy; Giriyanna Gowda; Ramesh Holla; Belludi Yajman Ashwin; Asutosh Padhi; Shamanna Manjula; Pradip Maganlal Patel
Journal:  Hum Vaccin Immunother       Date:  2013-09-12       Impact factor: 3.452

3.  Rabies virus infection in Eptesicus fuscus bats born in captivity (naïve bats).

Authors:  April D Davis; Jodie A Jarvis; Craig Pouliott; Robert J Rudd
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

4.  Factors associated with the success of rabies vaccination of dogs in Sweden.

Authors:  Louise T Berndtsson; Ann-Kristin J Nyman; Esteban Rivera; Berndt Klingeborn
Journal:  Acta Vet Scand       Date:  2011-03-25       Impact factor: 1.695

5.  Evaluation of ELISA for the detection of rabies virus antibodies from the thoracic liquid and muscle extract samples in the monitoring of fox oral vaccination campaigns.

Authors:  Tomislav Bedeković; Ivana Šimić; Nina Krešić; Ivana Lojkić; Željko Mihaljević; Ivica Sučec; Ivana Lohman Janković; Peter Hostnik
Journal:  BMC Vet Res       Date:  2016-05-10       Impact factor: 2.741

6.  Development in Immunoprophylaxis against Rabies for Animals and Humans.

Authors:  Sukdeb Nandi; Manoj Kumar
Journal:  Avicenna J Med Biotechnol       Date:  2010-01

7.  A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods.

Authors:  Mary J Warrell; Anna Riddell; Ly-Mee Yu; Judith Phipps; Linda Diggle; Hervé Bourhy; Jonathan J Deeks; Anthony R Fooks; Laurent Audry; Sharon M Brookes; François-Xavier Meslin; Richard Moxon; Andrew J Pollard; David A Warrell
Journal:  PLoS Negl Trop Dis       Date:  2008-04-23

8.  Experimental infection of foxes with European Bat Lyssaviruses type-1 and 2.

Authors:  Florence Cliquet; Evelyne Picard-Meyer; Jacques Barrat; Sharon M Brookes; Derek M Healy; Marine Wasniewski; Estelle Litaize; Mélanie Biarnais; Linda Johnson; Anthony R Fooks
Journal:  BMC Vet Res       Date:  2009-05-19       Impact factor: 2.741

9.  Rabies Virus Antibodies from Oral Vaccination as a Correlate of Protection against Lethal Infection in Wildlife.

Authors:  Susan M Moore; Amy Gilbert; Ad Vos; Conrad M Freuling; Christine Ellis; Jeannette Kliemt; Thomas Müller
Journal:  Trop Med Infect Dis       Date:  2017-07-21

10.  Molecular and serological survey of lyssaviruses in Croatian bat populations.

Authors:  Ivana Šimić; Ivana Lojkić; Nina Krešić; Florence Cliquet; Evelyne Picard-Meyer; Marine Wasniewski; Anđela Ćukušić; Vida Zrnčić; Tomislav Bedeković
Journal:  BMC Vet Res       Date:  2018-09-06       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.